Ruthia He, founder and former CEO of Done Global, was sentenced to 72 months in federal prison and fined $1 million for running a scheme that distributed more than 37 million pills of Adderall through a telemedicine subscription model. The case, docketed as 3:24-CR-329 in the Northern District of California, represents the Justice Department’s first criminal drug-distribution prosecution tied to telemedicine prescribing at a digital health company. Clinical president David Brody received a separate 24-month sentence for his role in the operation, which prosecutors valued at $90 million.
Why a six-year sentence for Done Global’s founder carries weight beyond one company
The sentencing sends a direct signal to every telehealth startup that built its growth around controlled-substance prescriptions during the pandemic. Done Global’s model offered patients fast, subscription-based access to stimulant medications, marketed as a frictionless way to obtain ADHD treatment without traditional in‑person visits. When pharmacies in multiple states began refusing to fill prescriptions written by Done-affiliated providers, the company did not slow down. Instead, prosecutors say He and Brody created a separate medical practice, Mindful Mental Wellness P.A., specifically to circumvent those pharmacy refusals and keep pills flowing to subscribers.
The Drug Enforcement Administration framed the outcome in blunt terms. DEA officials said the defendants’ conduct “flooded communities across the country with Adderall,” language that appears in the agency’s own press release on the sentencing. That framing matters because it positions the case not as a billing dispute or a regulatory technicality, but as unlawful drug distribution carried out through a digital health platform. By tying the conduct to community-level drug harm, the DEA is signaling that telemedicine is no shield against traditional narcotics enforcement tools, including investigations that focus on prescription volume, refill patterns, and geographic spread.
Telemedicine companies that scaled stimulant prescribing well above pre‑pandemic regional averages now face a measurably higher risk of DEA audits and parallel civil actions from insurers. The Northern District of California prosecution shows that federal authorities are willing to treat a telehealth startup like a conventional pill mill when prescription data, internal communications, and revenue flows line up. For founders and investors, the case undercuts the assumption that operating in a gray zone of pandemic-era flexibilities will be judged leniently once emergency rules expire. Instead, prosecutors have drawn a line: when growth strategies depend on high‑velocity prescribing of Schedule II drugs, criminal exposure is now a foreseeable risk.
The ripple effects extend beyond ADHD treatment. Other telehealth segments that rely on controlled substances-such as online pain clinics, anxiety and insomnia services that prescribe benzodiazepines, and opioid use disorder platforms-are likely to see closer scrutiny of their clinical protocols and marketing claims. Pharmacy chains and pharmacy benefit managers, already wary of high‑volume digital prescribers, may harden internal thresholds for blocking prescriptions linked to subscription-based platforms. Insurers, armed with the Done Global precedent, can more confidently challenge reimbursement for visits they view as perfunctory or designed primarily to generate drug orders rather than provide comprehensive care.
How prosecutors built the $90 million Adderall case against Ruthia He
The government’s case rested on the sheer volume of pills and revenue the operation generated. According to a detailed Justice Department summary, the scheme involved distributing more than 37 million Adderall pills nationwide and defrauding public and private insurers of over $12 million by submitting claims for medically unnecessary prescriptions and cursory telehealth visits. Prosecutors characterized the company’s subscription model as a mechanism to maximize prescription throughput, not to deliver individualized psychiatric care.
The underlying charging document filed in the Northern District of California goes further, describing how Done Global and its affiliated practice allegedly generated over $100 million in pandemic‑era revenue tied to Adderall and other stimulants. That indictment filing references more than 40 million pills when other Schedule II stimulants are included, and details internal policies that rewarded providers who wrote large numbers of prescriptions while limiting the time they spent with each patient. The discrepancy between the 37‑million figure cited at sentencing and the higher totals in the indictment likely reflects the difference between Adderall‑only counts and broader stimulant categories, as well as the gap between gross revenue and the narrower “scheme value” used for sentencing calculations.
Prosecutors emphasized several structural features of the business that, in their view, transformed an ostensibly legitimate telehealth service into a criminal enterprise. Marketing materials promised near‑instant ADHD diagnoses and rapid access to medication, creating strong expectations among prospective patients. Internal metrics tracked conversion from online questionnaire to prescription, putting pressure on contracted clinicians to approve drug therapy after minimal interaction. Safeguards such as comprehensive medical histories, collateral information from schools or employers, and routine follow‑up visits were either downplayed or bypassed entirely when they threatened subscription growth.
When pharmacy refusals began to threaten the business model, the creation of Mindful Mental Wellness P.A. allowed the same leadership to route prescriptions through a new entity, obscuring patterns that had triggered red flags. According to the government’s account, this was not a temporary compliance fix but a deliberate effort to maintain prescription volume in the face of mounting concerns from pharmacists and insurers. That decision became a key evidentiary bridge for prosecutors, demonstrating that He and Brody were aware of the risks yet chose to reconfigure the operation rather than reduce or reform it.
For digital health companies, the Done Global case now functions as a roadmap of what federal authorities will treat as criminal: growth strategies that hinge on cursory evaluations, algorithmic or quota‑driven prescribing, and workarounds when traditional safeguards intervene. The six‑year sentence for He and the two‑year term for Brody underscore that executives and clinical leaders share responsibility for how telemedicine models are implemented, not just how they are pitched to patients and investors.
Free for readers: The free Retirement Shield newsletter sends plain-English help keeping more of your money in retirement — the scams to dodge, the benefits you’re owed, and what’s changing with Social Security and Medicare, a couple times a week. Get the free newsletter.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
